Table 3 Cytogenetic abnormalities of MDS patients stratified by age groups

Genes mutation total events (mean)

1.78

1.64

1.95

0.216

 TET2

72 (77.4%)

41 (82.0%)

31 (72.1%)

0.255

 ASXL1

21 (22.6%)

10 (20.0%)

11 (25.6%)

0.521

 U2AF1

18 (19.4%)

10 (20.0%)

9 (20.9%)

0.912

 RUNX1

9 (9.7%)

3 (6.0%)

6 (14.0%)

0.196

 NRAS

7 (7.5%)

2 (4.0%)

5 (11.6%)

0.164

 TP53

5 (5.4%)

2 (4.0%)

3 (7.0%)

0.526

 SF3B1

5 (5.4%)

2 (4.0%)

3 (7.0%)

0.526

 DNMT3A

5 (5.4%)

2 (4.0%)

3 (7.0%)

0.526

 CEBPA

5 (5.4%)

3 (6.0%)

2 (4.7%)

0.774

 SRSF2

5 (5.4%)

0 (0%)

5 (11.6%)

N/A

 ETV6

4 (4.3%)

3 (6%)

1 (2%)

0.384

 SETBP1

3 (3.2%)

2 (4%)

1 (2%)

0.649

 JAK2

2 (2.3%)

0 (0%)

2 (5%)

N/A

 PHF6

1 (1.1%)

0 (0%)

1 (2%)

N/A

 NPM1

1 (1.1%)

0 (0%)

1 (2%)

N/A

 IDH2

1 (1.1%)

0 (0%)

1 (2%)

N/A

 EZH2

1 (1.1%)

1 (2%)

0 (0%)

N/A

 CBL

1 (1.1%)

1 (2%)

0 (0%)

N/A

DNA methylation (frequency, %)

72 (77.4%)

41 (82%)

31 (72.1%)

0.547

RNA spliceosome (frequency, %)

28 (30.1%)

12 (24%)

16 (37.2%)

0.166

Chromatin remodelling (frequency, %)

22 (23.7%)

11 (22%)

11 (25.6%)

0.685

Transcriptional deregulation (frequency, %)

14 (15.1%)

6 (12%)

8 (18.6%)

0.375

Activated signalling (frequency, %)

10 (10.8%)

3 (6%)

7 (16.3%)

0.111